+44 20 8123 2220
info@marketpublishers.com

Mixed CARE-MS I data – Good for BIIB!

https://marketpublishers.com/r/M26B640B418EN.html
Date: July 2011
Pages: 4
Price: US$ 90.00 (Single User License)
ID: M26B640B418EN

Abstracts

Sanofi/GENZ's Lemtrada (alemtuzumab, PhIII, RRMS) met the primary end point (reduction in relapse rate), but secondary endpoint- time to six month sustained accumulation of disability (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players in the MS field? Please read our report, released on 11th July, 2011, titled – "Mixed CARE-MS I data – Good for BIIB!"

+44 20 8123 2220
info@marketpublishers.com

Contents

COMPANIES MENTIONED

BIOGEN IDEC

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Mixed CARE-MS I data – Good for BIIB!
Product link: https://marketpublishers.com/r/M26B640B418EN.html
Price: US$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M26B640B418EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970